BusinessGeoVax Reports Q1 2026 Financial Results and Phase 3 Trial Plans
GeoVax, Inc. announced its financial results for the first quarter of 2026 and outlined plans for implementing the Phase 3 trial of its GEO-MVA vaccine. The report provides key financial data and updates on the clinical trial progress as of May 14, 2026.
Finanznachrichten.de·


